arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

JOHNSON & JOHNSON

JNJ
$272.34 ▼ -4.00 (-1.45%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
76 Visible periods
33 Metrics
Peer-ranked Benchmarks
Price Chart
76
Health
Good
Bullish
auto_awesome

Analytical Summary

JOHNSON & JOHNSON shows strong fundamentals with top-quartile Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $656.2B
Dividend Yield 0.49%
Revenue Growth 5.9% ↘
Op. Margin None
ROIC None
FCF / Share $2.64 ↘
Trailing P/E 3026.0x
Price / Book 8.1x
FCF Yield 1.0%
Debt / Equity 0.55
info Valuation on last close. End-of-day price, Nov 5, 2026.

76-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$25.40B
↑ +5.9% —
Net Income Profit after all expenses
$210.00M
↓ -95.9% —
Operating Margin Operating profit as % of sales
33.5%
↓ -12.2% —
FCF / Share Free cash flow per share
$2.64
↓ -12.9% —
Long-Term Debt Long-term obligations
$35.80B
↓ -4.1% —
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
86
Cash Quality ↓
50

Dividend History

Dividend / share · sourced from SEC filings
$5.14 Latest / share
+4.7% YoY
+5.8% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 20 years · 76 quarters